Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Impaired Hepatic Function: early-phase trial registry
A small indexed set (3 trials) with no open enrollment listed right now.
Corpus placement: #5,209 of 28,707 conditions by registered trial count.
3 US clinical trials · none currently recruiting · #5,209 of 28,707 conditions by registered trial count
Impaired Hepatic Function: 3 US clinical trials tracked, none currently recruiting.
Impaired Hepatic Function is the subject of 3 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 0 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is NGM Biopharmaceuticals, running 1 of these trials.
Enrollment posture brief
Registry condition impaired-hepatic-function
OPEN 0 | RECR 0% | LATE 0 | EARLY 3 | RANK #5209 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)
Impaired Hepatic Function has no open enrollment in this registry pull (3 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Impaired Hepatic Function on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Impaired Hepatic Function is recruiting below its size-band peers.
0 of 3 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Indexed trials (enrollment closed)
3 total, page 1 of 1
Study of Aldafermin (NGM282) in Participants With Impaired Hepatic Function
NGM Biopharmaceuticals
NCT04823702
Effect of Hepatic Impairment on LDE225..
Novartis Pharmaceuticals
NCT01764776
A Phase 1, Open-Label Study to Assess the Single-Dose Pharmacokinetics of Eravacycline in Subjects With Impaired Hepatic Function and Healthy Subjects
Tetraphase Pharmaceuticals
NCT02135302
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Impaired Hepatic Function records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Impaired Hepatic Function trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Impaired Hepatic Function page
3 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- No Impaired Hepatic Function trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- NGM Biopharmaceuticals sponsors the most Impaired Hepatic Function trials on record, review their full trial history before evaluating a specific study. See NGM Biopharmaceuticals's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Impaired Hepatic Function condition card totals 3 registered trials; most-linked intervention eravacycline; top US site state Florida. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.